文献速递慢性肾脏病血液净化与透析

移民慢性肾脏病患者潜伏性结核感染筛查的成本效果分析

Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis.
PubMed 文献 · Am J Kidney Dis · 2018-09-28

该研究利用加拿大不列颠哥伦比亚省的健康行政数据,构建离散事件模拟模型,评估在晚期慢性肾脏病(CKD)或开始透析的移民中进行潜伏性结核感染(LTBI)筛查的成本效果。结果显示,在开始透析且来自结核高发病率国家的患者中,IGRA筛查较不筛查成本更低且效果更好;在晚期CKD患者中,IGRA筛查仅对60岁及以上且来自高发病率国家者具有成本效果。

要点

  • 对开始透析的移民,IGRA筛查较不筛查成本更低且效果更好。
  • 晚期CKD移民中,IGRA筛查仅对≥60岁且来自结核高发病率国家者具成本效果。
  • IGRA筛查在所有情景下均优于结核菌素皮肤试验。

核心结论

  • 应考虑对开始透析的非加拿大出生居民及高龄晚期CKD患者进行LTBI筛查。

研究设计与样本

  • 基于加拿大不列颠哥伦比亚省1985-2012年永久居民健康行政数据的成本效果分析。
  • 采用离散事件模拟模型,医疗系统视角,1.5%贴现率,5年时间范围。

主要发现

  • IGRA筛查在所有情景下均优于结核菌素皮肤试验。
  • 开始透析且来自结核高发病率国家者,IGRA筛查较不筛查成本更低且结局更好。
  • 晚期CKD患者中,IGRA筛查仅对≥60岁且来自高发病率国家者具成本效果(每获得QALY成本<$48,000)。

关键数值与推荐

  • 筛查阳性者接受异烟肼治疗9个月。
  • 结局指标包括成本(2016年加元)、结核病例数和质量调整生命年(QALY)。

临床怎么用

  • 对开始透析的移民患者可考虑IGRA筛查LTBI。
  • 对晚期CKD移民患者,IGRA筛查应优先考虑≥60岁且来自结核高发病率国家者。

局限性

  • 研究结果向不同流行病学背景的推广受限。
  • 模型对复杂临床决策的模拟存在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: In countries with a low tuberculosis (TB) incidence, TB disproportionately affects populations born abroad. TB persists in these populations through reactivation of latent TB infection (LTBI) acquired before immigration. Those with chronic kidney disease (CKD) are at increased risk for reactivation and may benefit from LTBI screening and treatment. STUDY DESIGN: Health administrative data from British Columbia, Canada, were used to inform a cost-effectiveness analysis evaluating LTBI screening in those diagnosed with stage 4 or 5 CKD not requiring dialysis (late-stage CKD) and those who began dialysis therapy. SETTING & POPULATION: Permanent residents establishing residency in British Columbia, Canada, between 1985 and 2012 who had late-stage CKD diagnosed or began dialysis therapy. INTERVENTIONS: Screening with the tuberculin skin test or interferon-gamma release assay (IGRA) compared to no LTBI screening at the time of late-stage CKD diagnosis and time of dialysis therapy initiation. Treatment for those who tested positive was isoniazid for 9 months. OUTCOMES: Costs (2016 Can $), TB cases, and quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio for QALYs gained was calculated. MODEL, PERSPECTIVE, & TIMEFRAME: Discrete event simulation model using a health care system perspective, 1.5% discount rate, and 5-year time horizon. RESULTS: Screening with IGRA was superior to the tuberculin skin test in all situations. Screening with IGRA was less expensive and resulted in better outcomes compared to no screening in those initiating dialysis therapy from countries with an elevated TB incidence. In individuals with late-stage CKD, screening with IGRA was only cost-effective in those 60 years or older (cost per QALY gained, <$48,000) from countries with an elevated TB incidence. LIMITATIONS: This study has limitations in generalizability to different epidemiologic settings and in modeling complicated clinical decisions. CONCLUSIONS: LTBI screening should be considered in non-Canadian-born residents initiating dialysis therapy and those with late stage CKD who are older.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Campbell JR, Johnston JC, Ronald LA, et al. Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. Am J Kidney Dis. 2018. PMID: 30269868. doi:10.1053/j.ajkd.2018.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。